Company provides update on Phase III study of SARS-CoV-2 intravenous immune globulin (COVID-HIG) for hospitalised patients with Covid-19

Data from the Phase III ITAC (INSIGHT-013) trial show that the addition of antiSARS-CoV-2 hyperimmunoglobulin to standard of care (including remdesivir) was not associated with clinical benefit in hospitalised adults with Covid-19 and symptoms for <12 days.

Source:

Biospace Inc.